Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | PRKCA | P17252 | 4/20 | 0.33 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.33 |
| ▸ | PRKCG | P05129 | 3/20 | 0.33 |
| ▸ | PRKCB | P05771 | 3/20 | 0.33 |
| ▸ | PRKCH | P24723 | 3/20 | 0.33 |
| ▸ | PRKCE | Q02156 | 3/20 | 0.33 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.33 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.33 |
| ▸ | PRKD1 | Q15139 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL52102 | 1.00 | POLB (0.42) | POLBPRKCAPRKD3PRKCGPRKCB | |
| SCHEMBL7893349 | 1.00 | POLB (0.42) | POLBPRKCAPRKD3PRKCGPRKCB | |
| SCHEMBL2480467 | 1.00 | POLB (0.42) | POLBPRKCAPRKD3PRKCGPRKCB | |
| SCHEMBL1333553 | 1.00 | POLB (0.42) | POLBPRKCAPRKD3PRKCGPRKCB | |
| SCHEMBL12546111 | 0.87 | POLB (0.37) | POLBPRKCAPRKD3PRKCGPRKCB | |
| SCHEMBL18219141 | 0.87 | POLB (0.37) | POLBPRKCAPRKD3PRKCGPRKCB | |
| SCHEMBL15457672 | 0.87 | POLB (0.37) | POLBPRKCAPRKD3PRKCGPRKCB | |
| SCHEMBL10777104 | 0.80 | POLB (0.40) | POLBPRKCAPRKD3PRKCGPRKCB | |
| SCHEMBL20799266 | 0.79 | PRKCA (0.41) | PRKCAPRKD3PRKCGPRKCBPRKCH | |
| Aceglatone SCHEMBL8852 | 0.76 | POLB (0.39) | POLBPRKCAPRKD3PRKCGPRKCB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100145048-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION | 2010-06-10 | — | — | US | disclosed |
| US-7652020-B2 | novel hydantoin derivatives to inhibit matrix metalloproteinases (MMPs), a disintegrin and metalloproteases (ADAMs) and/or tumor necrosis factor alpha converting enzyme (TACE) and in so doing prevent the release of tumor necrosis factor alpha (TNF- alpha ); autoimmune diseases; side effect reduction | SCHERING CORPORATION (US) | 2010-01-26 | — | — | US | disclosed |
| US-7652020-B2 | novel hydantoin derivatives to inhibit matrix metalloproteinases (MMPs), a disintegrin and metalloproteases (ADAMs) and/or tumor necrosis factor alpha converting enzyme (TACE) and in so doing prevent the release of tumor necrosis factor alpha (TNF- alpha ); autoimmune diseases; side effect reduction | SCHERING CORPORATION (US) | 2010-01-26 | — | — | US | disclosed |
| US-7638513-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| US-7638513-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION | 2007-07-19 | — | — | US | disclosed |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-08-10 | — | — | US | disclosed |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | MMP12, ADAMTS1, ADAM33 | POLB 1159/4885PRKCA 3887/4885PRKD3 4828/4885 |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | MMP12, ADAMTS1, TNF | POLB 1908/4885PRKCA 3225/4885PRKD3 4767/4885 |
| US-20100145048-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TNF, MMP12, MMP8 | POLB 1552/4885PRKCA 2187/4885PRKD3 4051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.